Neratinib plus paclitaxel vs. trastuzumab plus paclitaxel in breast cancer

Posted by on April 14, 2016 3:34 pm
Tags:
Categories: health

While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with delayed onset and reduced frequency of central nervous system metastases, a finding that requires a larger study to confirm, according to an article.

Leave a Reply

Your email address will not be published.